Table 1.
Demographic and treatment characteristics for pediatric/adolescent survivors of neuroblastoma and siblings
| Characteristic | Survivors N (%) |
Siblings N (%) |
P-value |
|---|---|---|---|
| Total number | 859 | 872 | N/A |
| Sex | 0.35 | ||
| Female | 429 (49.9%) | 416 (47.7%) | |
| Male | 430 (50.1%) | 456 (52.3%) | |
| Race/ethnicity | 0.07 | ||
| White, non-Hispanic | 706 (82.2%) | 724 (83.0%) | |
| Black, non-Hispanic | 54 (6.3%) | 34 (3.9%) | |
| Hispanic/Latino | 44 (5.1%) | 45 (5.2%) | |
| Other | 55 (6.4%) | 69 (7.9%) | |
| Age at diagnosis (years) | N/A | N/A | |
| <1 | 534 (62.2%) | ||
| 1–1.99 | 184 (21.4%) | ||
| 2–4.99 | 123 (14.3%) | ||
| 5 and older | 18 (2.1%) | ||
| Age at baseline (years) | 0.04 | ||
| 8–11 | 157 (18.3%) | 145 (16.6%) | |
| 12–13 | 206 (24.0%) | 172 (19.7%) | |
| 14–15 | 250 (29.1%) | 261 (30.0%) | |
| 16–17 | 246 (28.6%) | 294 (33.7%) | |
| Overall treatmenta | |||
| Surgery only | 259 (32.8%) | N/A | N/A |
| Surgery+chemotherapy | 292 (37.0%) | ||
| Surgery+radiation | 59 (7.5%) | ||
| Surgery+chemotherapy+radiation | 163 (20.6%) | ||
| None/Other combinations | 17 (2.1%) | ||
| Specific treatment exposures, median cumulative dose for those who received dose > 0 |
|||
| Cranial radiation (cGy, n=220) | 20 (IQR: 20 – 525) | N/A | N/A |
| Chest radiation (cGy, n=221) | 700 (IQR: 200 – 1600) | ||
| Abdominal radiation (cGy, n=220) | 1200 (IQR: 200 – 2100) | ||
| Alkylating agent (gramsb, n=410) | 6180 (IQR: 4018 – 11434) | ||
| Platinum agent (mg/m2, n=238) | 755 (IQR: 360 – 1882.3) | ||
| Anthracycline (mg/m2, n=321) | 142 (IQR: 93.3 – 193.3) |
IQR = interquartile range
a
69 subjects did not consent to release of medical records for treatment exposures and were not included
b
Alkylating agent (i.e. cyclophosphamide, ifosfamide, procarbazine, chlorambucil, BCNU, CCNU, melphalan, Thio-TEPA, nitrogen mustard, busulfan) exposure was determined using cyclophosphamide equivalent dose, methodology previously published 49